Signature Diagnostics AG is a molecular diagnostics company based in Potsdam, Germany, focusing on the development and commercialization of novel molecular oncology diagnostic products for early detection (screening) and prognosis of cancer. The company has completed development of its first two diagnostic products for colorectal cancer screening (Detector C) and prognosis (Predictor C), which will be launched in 2012 in its own ISO 15189 certified service laboratory. Using its state-of-the-art technologies in tissue and blood sample collection, molecular pathology, Xenopatient(TM) platform, genome-wide profiling, data mining, and biostatistics, the company collaborates with clinical, pharmaceutical, and diagnostic partners. Signature Diagnostics sponsors and conducts large prospective, multicenter clinical trials with more than 33 primary care hospitals and several dozen colonoscopy centers in Germany to discover and validate biomarkers in oncology.

news


homepagecontactdirectionsimpressum